The Insider and Global Product Supply Officer of The Procter & Gamble Company (PG), Ioannis Skoufalos, Sold 4,098 Shares; Biolinerx LTD. – American Depositary Shares (BLRX) Shorts Down By 18.49%

June 13, 2018 - By John Hoffman

The Procter & Gamble Company (NYSE:PG) Logo

Biolinerx LTD. – American Depositary Shares (NASDAQ:BLRX) had a decrease of 18.49% in short interest. BLRX’s SI was 535,200 shares in June as released by FINRA. Its down 18.49% from 656,600 shares previously. With 366,800 avg volume, 2 days are for Biolinerx LTD. – American Depositary Shares (NASDAQ:BLRX)’s short sellers to cover BLRX’s short positions. The SI to Biolinerx LTD. – American Depositary Shares’s float is 0.84%. The stock increased 1.92% or $0.02 during the last trading session, reaching $1.06. About 84,536 shares traded. BioLineRx Ltd. (NASDAQ:BLRX) has risen 7.06% since June 13, 2017 and is uptrending. It has underperformed by 5.51% the S&P500. Some Historical BLRX News: ; 26/03/2018 – BIOLINE RX LTD – ADDITIONAL CORRESPONDING PATENT APPLICATIONS FOR AGI-134 ARE PENDING IN EUROPE, JAPAN, CHINA, CANADA, AUSTRALIA AND ISRAEL; 17/05/2018 – BIOLINE RX LTD – BL-8040 IN COMBINATION WITH CYTARABINE SHOWED SIGNIFICANTLY IMPROVED OVERALL SURVIVAL COMPARED TO HISTORICAL DATA IN TRIAL; 06/03/2018 – BioLine RX 2017 R&D Expenses $19.5 Million; 16/05/2018 – BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia; 17/05/2018 – BIOLINE RX LTD – BL-8040 WAS SAFE AND WELL TOLERATED; 22/05/2018 – BIOLINE RX LTD BLRX.TA – QTRLY LOSS PER ORDINARY SHARE BASIC AND DILUTED $0.06; 16/05/2018 – BIOLINERX GETS EUROPEAN PATENT COVERING USE OF BL-8040; 06/03/2018 – BioLine RX 2017 Loss/Shr 27c; 17/05/2018 – BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients; 26/03/2018 – BIOLINERX REPORTS NOTICE OF ALLOWANCE FROM USPTO

More news for BioLineRx Ltd. (NASDAQ:BLRX) were recently published by:, which released: “Biolinerx reports Q1 result” on May 22, 2018.‘s article titled: “BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2018 Results – Earnings Call Transcript” and published on May 22, 2018 is yet another important article.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $110.58 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 27 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by Oppenheimer given on Tuesday, September 26. H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) rating on Wednesday, January 17. H.C. Wainwright has “Buy” rating and $4.0 target. Oppenheimer initiated the stock with “Buy” rating in Thursday, December 21 report. Maxim Group maintained BioLineRx Ltd. (NASDAQ:BLRX) rating on Thursday, June 1. Maxim Group has “Buy” rating and $300 target. The rating was maintained by Oppenheimer with “Buy” on Tuesday, March 6. The rating was maintained by Oppenheimer with “Buy” on Monday, December 4. Roth Capital initiated it with “Buy” rating and $300 target in Thursday, August 3 report. On Monday, July 10 the stock rating was maintained by Maxim Group with “Buy”. The company was upgraded on Thursday, May 18 by Maxim Group. H.C. Wainwright maintained the shares of BLRX in report on Tuesday, May 22 with “Buy” rating.

Among 25 analysts covering Proctor & Gamble (NYSE:PG), 10 have Buy rating, 1 Sell and 14 Hold. Therefore 40% are positive. Proctor & Gamble has $106 highest and $61.0 lowest target. $90.02’s average target is 16.53% above currents $77.25 stock price. Proctor & Gamble had 90 analyst reports since August 4, 2015 according to SRatingsIntel. SunTrust maintained it with “Hold” rating and $7500 target in Thursday, April 19 report. RBC Capital Markets maintained the shares of PG in report on Monday, April 23 with “Hold” rating. The company was maintained on Friday, April 20 by Stifel Nicolaus. The stock has “Hold” rating by RBC Capital Markets on Friday, November 10. Stifel Nicolaus maintained The Procter & Gamble Company (NYSE:PG) on Friday, July 22 with “Buy” rating. The rating was downgraded by SunTrust to “Hold” on Thursday, December 22. UBS upgraded it to “Buy” rating and $96 target in Thursday, July 14 report. The firm earned “Neutral” rating on Monday, October 26 by UBS. The stock has “Buy” rating by Bank of America on Thursday, April 19. The stock of The Procter & Gamble Company (NYSE:PG) has “Hold” rating given on Monday, September 18 by Stifel Nicolaus.

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.11, from 0.89 in 2017Q4. It dropped, as 71 investors sold The Procter & Gamble Company shares while 786 reduced holdings. 112 funds opened positions while 556 raised stakes. 1.51 billion shares or 2.21% more from 1.47 billion shares in 2017Q4 were reported. Strategic Wealth Grp Inc Ltd Liability accumulated 94,270 shares or 0.46% of the stock. 15,528 were accumulated by Woodley Farra Manion Mngmt. Moors And Cabot holds 1.51% or 144,433 shares. Flippin Bruce & Porter holds 1.95% or 114,126 shares. Moreover, Liberty Capital Management Inc has 0.37% invested in The Procter & Gamble Company (NYSE:PG). First Dallas Secs reported 12,948 shares. Ssi Mngmt Inc has 0.05% invested in The Procter & Gamble Company (NYSE:PG). Sg Americas Securities Limited Liability Corporation invested 0.21% of its portfolio in The Procter & Gamble Company (NYSE:PG). The Minnesota-based Kopp Advsr Limited Liability Co has invested 0.63% in The Procter & Gamble Company (NYSE:PG). Washington Trust Bancorporation invested 1.23% in The Procter & Gamble Company (NYSE:PG). Murphy Pohlad Asset Lc owns 41,130 shares. Columbia Partners L L C Invest Mngmt invested in 0.03% or 3,110 shares. Aviva Public Llc invested 0.73% of its portfolio in The Procter & Gamble Company (NYSE:PG). New Jersey-based Regentatlantic Capital Limited has invested 0.19% in The Procter & Gamble Company (NYSE:PG). 5,414 were accumulated by S&T Fincl Bank Pa.

The Procter & Gamble Company provides branded consumer packaged goods to clients in the United States, Canada, Puerto Rico, Europe, the Asia Pacific, Greater China, Latin America, India, the Middle East, and Africa. The company has market cap of $194.25 billion. The companyÂ’s Beauty segment offers hair care products, including conditioners, shampoos, styling aids, and treatments; and skin and personal care products, such as antiperspirant and deodorant, personal cleansing, and skin care products. It currently has negative earnings. It markets its products under Head & Shoulders, Pantene, Rejoice, Olay, Old Spice, Safeguard, and SK-II brands.

The stock increased 0.01% or $0.01 during the last trading session, reaching $77.25. About 7,917 shares traded. The Procter & Gamble Company (NYSE:PG) has declined 14.45% since June 13, 2017 and is downtrending. It has underperformed by 27.02% the S&P500. Some Historical PG News: ; 17/04/2018 – CincinnatiBusCou: EXCLUSIVE: P&G manager joins Pure Romance to launch digital marketing; 29/03/2018 – Amazon Private Brands Will Expand into Pet Accessories, Diapers, Lawn & Garden and OTC in 2018, Report Indicates; 06/04/2018 – Can P&G Still Be Saved? —; 19/04/2018 – P&G: The $1 Billion Consumer Health Business of Merck KGaA Grew 6% Over the Past Two Years; 19/04/2018 – P&G KEEPS YR ORGANIC SALES GROWTH VIEW UP 2%-3%,SEES AT LOW END; 13/03/2018 – Nfusion Wins Gold for Deception Based Security in 2018 Info Security PG’s Global Excellence Awards; 27/03/2018 – Press release: Partners Group launches PG LIFE, an investment strategy focused on the UN’s Sustainable Development Goals; 18/04/2018 – P&G Nears Deal to Acquire Merck KGaA’s Consumer Health Unit; 19/04/2018 – P&G BOOSTS FORECAST FOR CORE EPS GROWTH; 19/04/2018 – PROCTER & GAMBLE OUTLOOK STABLE BY MOODY’S ON MERCK KGAA DEAL

Since February 15, 2018, it had 0 insider purchases, and 7 sales for $6.78 million activity. Schomburger Jeffrey K also sold $3.07 million worth of The Procter & Gamble Company (NYSE:PG) on Thursday, February 15. $113,533 worth of The Procter & Gamble Company (NYSE:PG) was sold by Coombe Gary A on Tuesday, May 15. 1,313 shares were sold by Fish Kathleen B, worth $103,190 on Wednesday, February 28. The insider Bishop Steven D sold 2,075 shares worth $149,130. Another trade for 8,502 shares valued at $668,179 was made by Pritchard Marc S. on Thursday, February 15. Posada Juan Fernando also sold $739,189 worth of The Procter & Gamble Company (NYSE:PG) shares.

As stated in the Washington-based SEC, a legal document for the transaction of 4,098 shares of Procter & Gamble Co by Ioannis Skoufalos was filled. Ioannis Skoufalos is at present the Global Product Supply Officer of the firm. The form was filled on June 12, 2018. These shares were sold at average $77.4 for every share, and had a value of $317,221 USD. Ioannis Skoufalos at the moment owns 0.0009% of the Company’s total market capitalization with ownership of 22,807 shares. 

Analysts await The Procter & Gamble Company (NYSE:PG) to report earnings on July, 26. They expect $0.91 earnings per share, up 7.06% or $0.06 from last year’s $0.85 per share. PG’s profit will be $2.29 billion for 21.22 P/E if the $0.91 EPS becomes a reality. After $1.00 actual earnings per share reported by The Procter & Gamble Company for the previous quarter, Wall Street now forecasts -9.00% negative EPS growth.

More notable recent The Procter & Gamble Company (NYSE:PG) news were published by: which released: “Lanny’s Recent Stock Purchase – Procter & Gamble” on June 09, 2018, also with their article: “Procter & Gamble Still the Dow’s Worst-Performing Stock” published on June 02, 2018, published: “The Procter & Gamble Company (NYSE:PG) Encouraging Extending Gains” on May 29, 2018. More interesting news about The Procter & Gamble Company (NYSE:PG) were released by: and their article: “Will The Real Offenders Please Stand Up?” published on June 12, 2018 as well as‘s news article titled: “Procter & Gamble Remains the Dow’s Worst Performing Stock” with publication date: May 26, 2018.

The Procter & Gamble Company (NYSE:PG) Institutional Positions Chart